HeyJaredBuonsenso&theKids
Outspoken views on child health, global health and pediatric infectious diseases
- Indexed issues, last 90 days
- 12
- Latest publication
- Sep 27, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 19, 2026
Latest issues
A mechanism, at last: new phase-II data show how low-dose rapamycin may work in ME/CFS (opens the original)
Read excerpt
A new paper in the Journal of Translational Medicine (Gile, Roy et al., 2026) is one of the most mechanistically detailed pieces of evidence yet for a treatment I’ve been building into the pharmacological framework for Long COVID/ME-CFS: low-dose rapamycin. It doesn’t just report that patients felt better — it traces a plausible biological path from drug, to enzyme, to metabolite, to microglial behavior, to fatigue.What was doneThis is a phase II observational, non-placebo-controlled study in 10
Your eyes remember: a new Nature Communications study strengthens the case for Long COVID as an immune-mediated disease (opens the original)
Read excerpt
A study just published in Nature Communications (Moustardas, Lagali et al., 2026) gives us one of the cleanest pieces of evidence yet that post-COVID syndromes are not “in people’s heads,” not functional, and not simply deconditioning. This time the organ under the microscope is the eye — and the findings map remarkably well onto the framework I’ve been describing for Long COVID and ME/CFS more broadly: a chronic, immune-mediated inflammatory condition with a plausible, targetable mechanism.What
A New Pediatric Paxlovid Study Opens a Door That Matters for Adolescent Long Covid (opens the original)
Read excerpt
Pediatrics published the EPIC-PEDS data, evaluating the pharmacokinetics and safety of nirmatrelvir/ritonavir (Paxlovid) in children aged 6 and older who are at risk of severe COVID-19 due to underlying conditions, with dosing calibrated by weight band (≥40 kg, and 20–40 kg). It’s an open-label phase 2/3 study whose primary objective was not to demonstrate clinical efficacy but to establish that the drug behaves safely and predictably in children younger and lighter than those previously covered
Is It Really — and Always — True That Bad Research Is Worse Than No Research? (opens the original)
Read excerpt
A while days ago a colleague I greatly respect (one of my fav pediatricians in Europe), and with whom I share much of the daily fight against infectious diseaseas, and coauthor of a number of publications, published a piece arguing that bad research is worse than no research at all. The argument is clear, and largely one I agree with: we are drowning in low-quality observational studies, often produced by researchers without adequate methodological training, published with little real scrutiny,
Case Report: Virtual-Clinic-Assisted Identification of a Long COVID/ME-CFS Phenotype and Clinical Response to Low-Dose Rapamycin — A Second Anonymised Case (opens the original)
Read excerpt
A technical case report from my virtual clinic (buonsenso-clinic.thekookbitcoiner.workers.dev)BackgroundThis is a second, independent case processed through the same structured virtual assessment pathway described in a previous report. As before, the tool combines standardised patient-reported outcome measures (PC-COS, PEM subscale) with structured intake of investigations already on file, and returns a preliminary working diagnosis, differential diagnosis, missing-investigation list, and staged
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.